NAUT — Nautilus Biotechnology, Inc.

Nautilus Biotechnology Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Operating Expenses: $15.4 million for Q4 2025, down 23% year-over-year; $66.8 million for the full year, down 18%.
• R&D Expenses: $41.1 million for FY 2025, a decrease of 19% from FY 2024, attributed to reduced lab supply costs and workforce optimization.
• G&A Expenses: $25.7 million for FY 2025, down 17% year-over-year, mainly due to lower stock-based compensation and professional service costs.
• Cash Position: Ended Q4 with $156.1 million in cash and equivalents; cash burn for 2025 was $50.2 million, down from $57.8 million in 2024.
• 2026 Guidance: Anticipated total operating expenses to increase by 15-20% and cash burn to range between $65 million to $70 million.

2. Strategic Updates and Business Highlights

• Product Development: Successful unveiling of the Nautilus Voyager instrument at the US HUPO conference, receiving positive feedback from the research community.
• Early Access Program: Launched in January 2026, allowing partners to engage with the Tau proteoform assay, aimed at facilitating biological discovery and supporting research.
• Collaborations: New partnership with Weill Cornell Medicine-Qatar and The Michael J. Fox Foundation to develop an alpha-synuclein proteoform assay, with $1.2 million funding for Nautilus.
• Technical Progress: Advancements in the broad-scale assay configuration and initial data from new chips indicate improved platform performance.

3. Forward Guidance and Outlook

• Revenue Expectations: Modest service revenue anticipated in 2026, with a significant revenue ramp expected in 2027 as instrument shipments commence.
• Commercial Launch: Planned for late 2026, with preorders for the Voyager platform and initial customer installations starting in early 2027.
• Future Assays: Expansion into oncology-focused proteoform assays is planned for the second half of 2026.

4. Bad News, Challenges, or Points of Concern

• Revenue Generation: No significant revenue expected from the Early Access Program in 2026; initial revenue projections are modest, primarily from grant funding.
• Sales Capacity: Currently no sales personnel in place, which may hinder immediate revenue generation and customer engagement efforts.
• Market Competition: The company faces competitive pressures in the proteomics space, necessitating effective differentiation and customer acquisition strategies.

5. Notable Q&A Insights

• Technical Milestones: Key achievements include finalizing the Tau proteoform assay and instrument readiness, with positive feedback from early customers regarding data quality.
• Sales Funnel Development: The company is beginning to build its sales capacity, with targeted hiring planned to support commercial efforts.
• Customer Feedback: Early access customers expressed excitement about the quality of data produced, highlighting its potential to reveal insights into disease mechanisms, particularly in neurodegeneration.

Overall, Nautilus Biotechnology demonstrated strong operational discipline in Q4 2025, marked by significant cost reductions and strategic advancements in product development, while preparing for a pivotal year ahead in 2026.